BIIB 061

Drug Profile

BIIB 061

Alternative Names: BIIB061

Latest Information Update: 09 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class
  • Mechanism of Action Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 09 Aug 2016 Biogen plans a phase II trial for Multiple sclerosis in 2016 (Biogen website, August 2016).
  • 31 May 2016 Biogen Idec completes a phase I trial in Healthy volunteers in USA (NCT02228707)
  • 01 Jul 2015 Biogen initiates enrolment in a phase I pharmacokinetics trial for Multiple sclerosis (In volunteers) in USA (PO, Capsule, New formulation) (NCT02521545)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top